LA JOLLA PHARMACEUTICAL CO Uncategorized Contracts & Agreements
88 Contracts & Agreements
- Support Agreement, dated as of July 10, 2022, by and among the Parent, the Purchaser and the stockholders named therein (Filed With SEC on July 11, 2022)
- Description of Securities (Filed With SEC on March 9, 2022)
- PAION AG Exclusive Licensing Agreement, dated January 12, 2021 (Filed With SEC on March 8, 2021)
- Amendment, dated as of December 5, 2017, by and between the Registrant and the President and Fellows of Harvard College, as amended (Filed With SEC on March 8, 2021)
- Form of Contingent Value Rights Agreement, by and between La Jolla and the Rights Agent (Filed With SEC on June 24, 2020)
- Description of Securities (Filed With SEC on March 2, 2020)
- Revenue Interest Agreement, dated May 10, 2018, among La Jolla Pharma, LLC, HealthCare Royalty Partners III, L.P., HCRP Overflow Fund, L.P. and HCR Molag Fund, L.P (Filed With SEC on May 14, 2018)
- Dated:March 16, 2015/s/ Dennis M. MulroyDennis M. Mulroy (Filed With SEC on April 10, 2015)
- CONSENT AND AMENDMENT AGREEMENT (Filed With SEC on January 20, 2012)
- LA JOLLA PHARMACEUTICAL COMPANY (Filed With SEC on January 20, 2012)
- SECOND AMENDMENT AGREEMENT (Filed With SEC on August 25, 2011)
- AMENDMENT AGREEMENT (Filed With SEC on July 5, 2011)
- CONSENT AND AMENDMENT AGREEMENT (Filed With SEC on April 5, 2011)
- Current assets (Filed With SEC on November 12, 2010)
- Current assets (Filed With SEC on May 18, 2009)
- Current assets (Filed With SEC on May 18, 2009)
- Current assets (Filed With SEC on May 18, 2009)
- Current assets (Filed With SEC on May 18, 2009)
- Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them (Filed With SEC on March 31, 2009)
- Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them (Filed With SEC on March 31, 2009)
- Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them (Filed With SEC on March 31, 2009)
- Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them (Filed With SEC on March 31, 2009)
- Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them (Filed With SEC on March 31, 2009)
- Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them (Filed With SEC on March 31, 2009)
- Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them (Filed With SEC on March 31, 2009)
- Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them (Filed With SEC on March 31, 2009)
- Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them (Filed With SEC on March 31, 2009)
- AMENDMENT NO. 1 TO AMENDED AND RESTATED RIGHTS AGREEMENT (Filed With SEC on January 26, 2009)
- Entry into a Material Definitive Agreement (Filed With SEC on May 14, 2008)
- Entry into a Material Definitive Agreement (Filed With SEC on May 7, 2008)
- Entry into a Material Definitive Agreement (Filed With SEC on May 7, 2008)
- * * * (Filed With SEC on March 4, 2008)
- Current assets (Filed With SEC on August 7, 2007)
- Current assets (Filed With SEC on August 7, 2007)
- Focus on higher doses all new patients entering the study will be randomized in equal numbers to receive weekly doses of either 300 mg or 900 mg of Riquent or placebo, with no... (Filed With SEC on March 16, 2007)
- Focus on higher doses all new patients entering the study will be randomized in equal numbers to receive weekly doses of either 300 mg or 900 mg of Riquent or placebo, with no... (Filed With SEC on March 16, 2007)
- Current assets (Filed With SEC on August 8, 2006)
- /s/ Michael Tansey 7/14/06 Michael Tansey, BSc, MB ChB, MD, FFPM Date (Filed With SEC on July 18, 2006)
- AMENDMENT NO. 3 TO RIGHTS AGREEMENT (Filed With SEC on March 1, 2006)
- AMENDMENT NO. 2 TO RIGHTS AGREEMENT (Filed With SEC on December 16, 2005)
